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Anionic exchange resins are bona fide cholesterol-lowering agents with glycemia lowering actions in
diabetic patients. Potentiation of intestinal GLP-1 secretion has been proposed to contribute to the glycemia
lowering effect of these non-systemic drugs. Here, we show that resin exposure enhances GLP-1 secretion
and improves glycemic control in diet-induced animal models of ‘‘diabesity’’, effects which are critically
dependent on TGR5, a G protein-coupled receptor that is activated by bile acids.We identified the colon as a
major source of GLP-1 secretion after resin treatment. Furthermore, we demonstrate that the boost in
GLP-1 release by resins is due to both enhanced TGR5-dependent production of the precursor transcript of
GLP-1 as well as to the local enrichment of TGR5 agonists in the colon. Thus, TGR5 represents an essential
component in the pathway mediating the enhanced GLP-1 release in response to anionic exchange resins.
B
ile acids (BAs) aremolecules synthesized from cholesterol. They are composed of a sterol nucleus, a variable
number of hydroxyl groups and a side chain with a carboxyl group that can be conjugated to taurine or
glycine. The amphipathic nature of bile acids is essential for the emulsification and subsequent absorption
of dietary lipids and fat-soluble vitamins. In addition to their established role in dietary lipid absorption, BAs have
also emerged as important signaling molecules in various aspects of metabolic homeostasis1-4. Both nuclear and
membrane receptors have been shown to mediate the transduction of bile acid signals into adaptive cellular
responses. While the genomic effects of BAs are mainly governed by the nuclear receptor FXR, many of the rapid
non-genomic effects have been attributed to activation of the membrane receptor TGR5.
TGR5 (Gpbar1, GPR131, M-BAR) is a G protein-coupled receptor, which upon binding by BAs stimulates
downstream cAMP signaling pathways in a wide array of tissues and cell types5,6. Functional activation of TGR5
leads to the regulation of several physiological pathways that control BA and metabolic homeostasis. Actions of
TGR5 relevant to BA homeostasis are evident from the observation that mice lacking TGR5 have a reduced BA
pool size7,8 and from the finding that TGR5 activation promotes chloride and fluid secretion in gallbladder
epithelium9. TGR5 activation also prevents body weight gain and hepatic steatosis during high fat feeding10,11
and inhibits inflammatory responses5,12-14. These properties of TGR5 suggest that its activation could beneficially
impact on several features of the metabolic syndrome.
In the gut, BA dependent activation of TGR5 signaling improves glucose homeostasis by inducing glu-
cagon-like peptide-1 (GLP-1) secretion11,15. The incretin, GLP-1, is a gut peptide derived from the precursor,
preproglucagon, which is synthesized in the enteroendocrine L-cells of the intestinal epithelium16. Upon food
ingestion, GLP-1 is released in the circulation causing a wide range of endocrine effects that directly or
indirectly impact postprandial glucose homeostasis. The insulinotropic action of GLP-1 in pancreatic b-cells
has been shown to mediate the glucose lowering effect of GLP-1, however, other GLP-1-dependent mechan-
isms, such as reduction of gastric emptying and food intake, also contribute to this effect17–20. Interestingly,
recent evidence suggests that anionic exchange resins (AERs), which are non-absorbed polymers with bile
acid sequestering properties, can improve glycemic control in type 2 diabetes21–25. Enhanced GLP-1 secretion
has been proposed to account for the glucose lowering action of AERs26–29, but the molecular basis by which
AERs increase GLP-1 secretion is still largely unexplored. GLP-1-producing enteroendocrine L-cells are
highly enriched in colon, yet only minimal levels of BAs effectively reach the colon under physiological
conditions. This is caused by the efficient re-uptake of BAs by the epithelial cells of the ileum, which is an
integral part of the enterohepatic recycling of BAs. We therefore hypothesized that increasing the BA delivery
to the colon with AERs may potentiate the TGR5-GLP-1 pathway. In the current study we demonstrate that
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TGR5 is essential for the AER-mediated increase in GLP-1 release
and that the colon is a major site that accounts for this effect.
Results
AER-mediated stimulation ofGLP-1 release is abolished inTGR5-
deficient mice. To test the hypothesis that TGR5 mediates the
enhanced GLP-1 release induced by AERs, we treated TGR52/2
and TGR51/1 mice with Colestilan30. Colestilan treatment,
administered to the mice by food admix at a dose of 20 g/kg of
food (2% w/w), was initiated in mice 12 weeks after start of the
high fat diet. After two weeks of treatment, several plasma and
fecal lipid parameters were assessed. Administration of AERs
decreased LDL-cholesterol in TGR51/1 mice, whereas HDL- and
total-cholesterol levels remained unaffected (Table 1). AER
treatment also enriched fecal excretion of phospholipids, glycerol
derivatives and non-esterified fatty acids to a similar extent in both
genotypes (Table 1), except for the phospholipids, which were
already high in the untreated TGR52/2 mice. As expected, AER
treatment enriched fecal BA levels, although these levels were
lower in both untreated and AER-treated TGR52/2 mice, which is
consistent with the reduced BA pool size in TGR52/2 mice7,8.
In accordance with previous reports28,31,32, treatment with AERs
robustly induced GLP-1 secretion in wildtype mice after a test meal
(Fig. 1a). In TGR52/2 littermates, however, this response was
severely blunted (Fig. 1b), indicating that TGR5 is an essential com-
ponent in mediating the resin-induced increase in plasma GLP-1.
We next investigated glucose homeostasis in obese and insulin res-
istant animals treated for two weeks with Colestilan. Test meal-
induced insulin (Fig. 1c and 1d) and glucose (Fig. 1e and 1f) levels
were significantly reduced in plasma of AER-treated TGR51/1 mice
whereas these effects were less pronounced in TGR52/2 mice. Resin
treatment reduced body weight similarly across genotypes (Table 1),
indicating that the differences in glucose handling were not the con-
sequence of changes in body weight. These findings suggest that the
TGR5-dependent improvement in glucose homeostasis in response
to AERs may result from enhanced GLP-1 action.
TGR5 activation induces proglucagon gene expression and
promoter activity in enteroendocrine cells. In order to gain
insight into the mechanisms underlying the TGR5-dependent
secretion of GLP-1 upon AERs, we first assessed expression of TGR5
in different sections of the intestine. We observed that AERs did not
modulate TGR5 expression in the intestine, as TGR5 mRNA levels in
Colestilan-treated TGR51/1 intestinal sections were indistinguishable
from those of untreated TGR51/1 mice (Fig. 2a). Interestingly, in
addition to enhanced GLP-1 secretion, mRNA levels of proglucagon,
encoding the precursor of GLP-1, were also significantly increased in
the colons of AER-treated TGR51/1 mice relative to untreated
TGR51/1 mice. This increase in proglucagon mRNA was not
observed in TGR52/2 mice (Fig. 2b). Although not statistically
significant, a similar trend for proglucagon expression was found in
the ileum (Fig. 2b). To investigate the mechanism by which TGR5
regulates proglucagon gene expression, TGR5 was silenced in cultured
STC-1 and GLUTag mouse enteroendocrine cells using shRNA
constructs. Proglucagon mRNA levels were then assessed in the
absence or presence of the semi-synthetic cholic acid derivative and
TGR5-specific agonist, 6a-ethyl-23(S)-methyl-cholic acid, referred to
as INT-77711,33. Interestingly, INT-777 robustly induced proglucagon
mRNA levels in both cell lines, whereas no induction was observed in
cells in which endogenous TGR5 expression was repressed (Fig. 2c and
2d). TGR5 activation is known to induce cAMP signaling and the
proglucagon gene is an established target of cAMP signaling34–37. To
obtain more mechanistic insight into the TGR5-mediated induction of
proglucagon mRNA, we measured the activity of the proglucagon
promoter by transfecting STC-1 and GLUTag cells with a luciferase
reporter driven by the 2.3 kb upstream regulatory region of the
proglucagon gene, which contains several cAMP responsive
elements34–37. In line with the TGR5-dependent increase of colonic
proglucagon gene expression after AERs (Fig. 2b), INT-777
significantly induced proglucagon promoter activity in STC-1 and
GLUTag cells. This effect was significantly blunted upon shTGR5
transfection, indicating that TGR5 is critical in mediating the
increase of proglucagon promoter activity in response to INT-777
(Fig. 2e and 2f).
Acute Colestilan treatment enhances GLP-1 release in a TGR5-
dependent manner. In addition to the known cholesterol- and
glucose-lowering effects, AERs also curb body weight gain29,30,38,39.
Although the mechanism for body weight loss is not entirely
understood, it is generally accepted that sequestration of BAs by
AERs largely contributes to the observed caloric loss, as a result of
impaired mixed micelle formation and lipid absorption in the upper
part of the small intestine. In our study, two weeks of resin treatment
was already sufficient to induce a substantial reduction in body
weight as well as an increase in fecal lipid loss in both TGR52/2
and TGR51/1 mice (Table 1). To assess body weight independent
actions of AERs on GLP-1 secretion, we also investigated the effects
of acute administration of Colestilan in TGR52/2 and TGR51/1 mice
fed a high fat diet during 12 weeks. Interestingly, we observed that
three hours of Colestilan feeding was sufficient to double GLP-1
levels after a test meal in TGR51/1 mice, while no such effect was
observed in TGR52/2 animals (Fig. 3a and 3b). These data indicate
Table 1 | Biochemical measurements in plasma and feces of control and Colestilan-treated TGR51/1 and TGR52/2 mice
TGR5 1/1 TGR5 1/1 TGR52/2 TGR52/2
Control Colestilan Control Colestilan
Final body weight (g) 58.94 6 0,93 53.84 6 0,77a 58.61 6 1,94 53.71 6 2,09a
Plasma
LDL-cholesterol (mM) 0.42 6 0.02 0.35 6 0.03a 0.39 6 0.05 0.32 6 0.03
HDL-cholesterol (mM) 4.50 6 0.16 4.43 6 0.21 4.49 6 0.22 4.22 6 0.19
Total cholesterol (mM) 5.48 6 0.14 5.19 6 0.20 5.55 6 0.32 5.03 6 0.24
Feces
Fecal weight (mg/day/g BW) 12.30 6 3.54 33.08 6 3.23a 11.876 2.35 30.39 6 4.23a
Glycerol derivatives (mg/mg) 0.18 6 0.02 0.58 6 0.09a 0.24 6 0.03 0.60 6 0.09a
Total cholesterol (mg/mg) 3.88 6 1.23 4.23 6 0.91 3.23 6 1.78 3.98 6 1.23
Free fatty acids (mg/mg) 5.45 6 1.56 10.34 6 2.34a 6.23 6 1.34 11.19 6 3.29a
Phospholipids (mg/mg) 3.39 6 0.62 7.98 6 1.92a 11.13 6 3.23b 9.29 6 0.43
Total bile acids (mmol/g) 4.09 6 1.10 10.29 6 0.98a 2.22 6 0.34b 6.87 6 1.23a,b
Colestilan 2% was supplemented in the diet for 2 weeks after 12 weeks of high fat feeding. Values represent mean 6 SE.
aStatistically significant as compared to corresponding control group, p,0.05.
bStatistically significant between genotypes, p,0.05.
www.nature.com/scientificreports
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that TGR5 is also critical in mediating the acute effects of AERs on
GLP-1 secretion.
AERs potentiate GLP-1 release by delivering TGR5 agonists to the
distal gut.Our observations indicate that long-term exposure of AERs
triggers the induction of proglucagon gene expression in the distal gut.
However it is unlikely that the previously observed transcriptional
mechanism would entirely account for the rapid increase in
circulating GLP-1 observed as shortly after resin treatment. We
therefore hypothesized that AERs may also stimulate GLP-1 release
by increasing the local availability of natural TGR5 agonists in the gut.
To test this hypothesis, we first mapped the sites of GLP-1 release by
monitoring GLP-1 secretion in several ex vivo cultured sections of the
intestinal tract. Consistent with the enrichment of enteroendocrine L-
cells in more distal gut segments40, ileal and colonic explants, but not
duodenal explants, displayed the capacity to release GLP-1 (Fig. 4a).
Secretion of GLP-1 from colonic explants, however, was about 5-fold
above that observed in ileal explants, indicating that colon is a major
site of GLP-1 release in the intestinal tract (Fig. 4a). Exposure of
colonic explants to either INT-777 or a mixture of natural bile
acids, including litocholic acid (LCA) and deoxycholic acid (DCA)
robustly potentiated GLP-1 release from explanted colon sections of
TGR51/1, but not from TGR52/2 mice (Fig. 4b), which is consistent
with previous studies showing that activation of TGR5 in
enteroendocrine cells by natural and semi-synthetic BAs induces the
release of GLP-111,15,41. Interestingly, treating mice for two weeks with
Colestilan also induced GLP-1 release in colon sections maintained ex
vivo (Fig. 4c). This response was completely lost in the explants from
TGR52/2 mice, further supporting the critical role of TGR5 in this
process (Fig. 4c). To evaluate whether AER administration promotes
the delivery of TGR5 agonists to the distal gut, we collected the colon
content of untreated mice and mice treated for two weeks with
Figure 1 | Potentiation of GLP-1 secretion by AERs is TGR5-dependent. (a–f) Analysis of plasma from diet-induced obese TGR51/1 and TGR52/2 mice
after two weeks of treatment with Colestilan (COL; n57 per group). GLP-1 (a–b), insulin (c–d), and glucose (e–f) levels at indicated time points after test
meal. Data represent mean 6 SE. *Statistically significant, p,0.05, **p,0.01, ***p,0.001.
www.nature.com/scientificreports
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Colestilan and assessed their potency to activate TGR5 dependent
cAMP response element (CRE) binding protein (CREBP) activation
in CHO cells that were transfected with a TGR5 expression construct
and a CRE driven luciferase reporter. Interestingly, while colon
content from untreated mice only moderately increased luciferase
activity in the presence of TGR5, a much more robust effect could
be observed when cells were stimulated by the colon content from
mice that were treated with Colestilan (Fig. 4d). The extent of
activation by the colonic content of treated mice was also within the
same range of activation by the TGR5 agonist, LCA, which served as a
positive control in this experiment. We then evaluated whether TGR5
activation by the colon content from AER-treated mice is coupled to
enhanced GLP-1 secretion using cultured colon segments. Consistent
with our hypothesis, exposure of colon explants from TGR51/1 mice
with colon content from AER-treated wildtype mice significantly
induced GLP-1 release from the colon explants (Fig. 4e). This
potentiating effect was again significantly blunted when colon
explants from TGR52/2 mice were exposed to colon content derived
from AER-treated wildtype mice (Fig. 4e). No significant increase in
GLP-1 secretion however was found upon exposure of control colon
content to colon explants from both TGR51/1 and TGR52/2 mice.
Altogether, these data provide evidence that colonic TGR5 is an
essential component of AER-mediated stimulation of GLP-1 release
from the intestinal L-cell.
Discussion
Several clinical studies reported the efficacy of AERs in the regulation
of glycemic control24,42,43. In the current study, we provide evidence
that the potentiating effects of AERs onGLP-1 secretion are critically
dependent upon the G protein-coupled receptor TGR5. Our data
indicate that AERs enhance delivery of natural TGR5 agonists to
the colon and induce the expression of the GLP-1 precursor, pre-
proglucagon, in a TGR5-dependent manner.
Figure 2 | Enhanced proglucagon transcription in enteroendocrine cells in response to INT-777 requires TGR5. (a–b) TGR5 (a) and proglucagon (b)
mRNA levels in the different intestinal sections of diet-induced obese TGR51/1 and TGR52/2 mice after two weeks of treatment with Colestilan (COL;
n57 per group). (c–d) Proglucagon mRNA levels in STC-1 (c) and GLUTag (d) mouse enteroendocrine cells transfected with shControl or shTGR5
vectors in the presence of 30 mM INT-777 (black bars) or vehicle (white bars; n53 per group). (e–f) INT-777 induces proglucagon promoter activity via
TGR5 in enteroendocrine cells. STC-1 (e) and GLUTag (f) mouse enteroendocrine cells were transfected with shControl or shTGR5 constructs in
combinationwith the proglucagon luciferase reporter. Cells were then incubatedwith vehicle (white bars) or 30 mM INT-777 (black bars; n53 per group)
for 3 hours and assayed for luciferase activity. Data represent mean 6 SE. *Statistically significant, p,0.05.
Figure 3 | TGR5-dependent GLP-1 secretion is induced by acute exposure of AERs. (a–b) Plasma GLP-1 levels at indicated time points after test meal
from high fat diet-induced obese TGR51/1 mice (a) and TGR52/2 littermates (b) after three hours of treatment with Colestilan (COL; n57 per group).
Data represent mean 6 SE. *Statistically significant as compared to control group, p,0.05.
www.nature.com/scientificreports
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In the past, multiple mechanisms have been proposed to
explain the anti-diabetic effect of AERs. Most of these mechan-
isms invoked the BA sequestering properties of AERs and the
resulting effects on BA signaling. In agreement with their role
to interrupt the enterohepatic recirculation of BAs, AERs increase
cholesterol and BA synthesis44. Despite the observation that resins
render the BA pool more hydrophilic, no direct link between BA
composition and glucose lowering has been demonstrated45. The
glucose lowering effect of AERs has also been proposed to stem
from changes in FXR activity in response to AERs46. Consistent
with this hypothesis, AERs reduce blood levels of FGF15/1932,
which is an established FXR target in the intestine. Yet none
of these hypotheses so far have been able to link AERs with
enhanced GLP-1 release, an effect that is consistently observed
after AER administration28,29,31.
In an attempt to understand the mechanistic basis of enhanced
GLP-1 release in response to AERs, we have focused on the role of
TGR5 in this process. Our hypothesis was based on previous findings
from our laboratory indicating that BAs in the lumen of the intestine
activate TGR5, stimulating the subsequent release of GLP-1. Unlike
previous reports31, TGR5 mRNA expression was unchanged in res-
ponse to Colestilan exposure, indicating that under our experimental
conditions, AERs are not affecting TGR5 gene expression in entero-
endocrine cells. In contrast, Colestilan increased proglucagon
mRNA levels in the colon in a TGR5-dependent manner, suggesting
that resins enhance the transcription of the GLP-1 precursor gene in
the enteroendocrine L cells of the distal gut. In agreement with this,
TGR5 activation robustly induced the proglucagon promoter in
enteroendocrine STC-1 and GLUTag cells, while this effect was sig-
nificantly attenuated in cells in which TGR5 expression was silenced.
The enhanced proglucagon promoter activity in response to TGR5
activation is in line with the fact that TGR5 induces cAMP signaling,
which activates several cAMP responsive elements in the preproglu-
cagon promoter34–37.
In this study, we did not observe significant changes in body
weight between genotypes upon resin treatment. This could suggest
that the body weight lowering action of TGR5 agonists is only effec-
tive when agonists can reach the systemic circulation. This would
also be consistent with our previous studies showing that increased
levels of plasma bile acids in high fat fed mice can induce energy
expenditure and protect against diet-induced obesity10. In fact, AERs
prevent bile acids from reaching the circulation while on the other
hand they significantly concentrate bile acids in the intestinal lumen.
At present, it is not unequivocally established whether basolateral or
luminal TGR5 activation in enteroendocrine cells is important for
GLP-1 secretion. Given the sequestering role of AERs, our current
data would rather suggest an activation occurring at the luminal side
of the enteroendocrine L cells, although we cannot exclude the
Figure 4 | TGR5 signaling is induced by colon content of mice treated with AERs. (a) GLP-1 release from explants of different intestinal segments of
TGR51/1 mice. Duodenum (duo). (b) GLP-1 release from colon explants of TGR51/1 and TGR52/2 mice (n56 per group) in response to 1 hour
treatment with 30 mMINT-777 or 15 mMLCA/DCA.Micewere fed a high fat diet for 10weeks prior to the collection of explants. (c) GLP-1 secretion from
colon explants of TGR51/1 and TGR52/2 mice fed a high fat diet for 2 weeks and subsequently treated with Colestilan for two additional weeks (n56 per
group). (d) Luciferase activity in CHO cells transiently transfected with TGR5 expression vector and a cAMP response element (CRE)-driven luciferase
reporter vector. Cells were treated with DMSO vehicle (white bars), 10 mM litocholic acid (LCA; black bars), colon content collected from untreated
wildtypemice (light gray bars), or colon content collected fromColestilan-treated wildtypemice (dark gray bars; n55 per group). Themice cohorts used
for the collection of colon content were fed a high fat diet for 10 weeks prior treatment with Colestilan for 2 weeks. (e) GLP-1 release from colon explants
of TGR51/1 and TGR52/2 mice (n56 per group) in response to 1 hour exposure of colon content derived from untreated wildtypemice (light gray bars),
or colon content collected from Colestilan-treated wildtype mice (n55 per group). Data represent mean 6 SE. *Statistically significant, p,0.05;
**: p,0.01.
www.nature.com/scientificreports
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possibility that small, but sufficient amounts of free bile acids can still
reach the intestinal capillary system.
Most striking was the observation that Colestilan was able to
rapidly induce GLP-1 release within three hours of administration.
Interestingly, the colon content of AER-treated mice, but not that
from untreated mice, enhanced GLP-1 release, suggesting that AERs
may enrich the colon with TGR5 agonists. Given that TGR5 is a bile
acid receptor, bile acids represent ideal candidates to fulfill this role,
especially since the effect of AERs on GLP-1 release are strictly
TGR5-dependent. It should be noted that bile acids are likely to
activate TGR5 in their unbound form and that hence the ratio of
bound: unbound bile acids in the colon following AER treatment
may be critical. Furthermore, we postulate that the significant
enrichment of other anionic biomolecules than BAs, such as phos-
pholipids (Table 1) may ultimately increase the luminal ratio of free
versus bound BAs in the distal gut area. This shift towards higher
concentration of free BAs would in turn trigger TGR5 activity in the
enteroendocrine L-cell of the colon, a hypothesis supported by our ex
vivo data. Within this context, it is also noteworthy that TGR52/2
mice exhibit increased levels of fecal phospholipids already under
basal conditions, suggesting that TGR5 is likely essential for normal
phospholipid absorption and homeostasis.
Finally, the rapid and transient increase of GLP-1 in response to a
test meal remains an observation that is still not completely under-
stood. As only a small percent of a liquid load reaches the murine
distal small intestine within 30 minutes, the finding that test meal-
stimulated GLP-1 release was increased 10 min after oral gavage in
treated mice suggests that indirect neuro-endocrine mechanisms
may also contribute. The L-cell has been shown to be responsive to
many cues triggered by the presence of nutrients in the proximal gut.
Studies in rodents suggest that gastric inhibitory peptide (GIP) and
gastrin-releasing peptide (GRP) could bemediators of this proximal-
distal loop via activation of acetylcholine-dependent neuronal path-
ways47,48. In view of the expression of TGR5 in mesenteric neurons49,
further studies with neuron-specific somatic TGR5 mutants may
enable us to address this question.
In conclusion, our data provide evidence that the colon is a major
source of enhanced GLP-1 secretion after administration of AERs.
Resins increase GLP-1 secretion via activation of TGR5 and improve
glycemic control in diet-induced models of obesity and insulin res-
istance.Moreover, we illustrate that AERs increase proglucagon gene
promoter activity, resulting in increased proglucagon transcript
levels. These findings may reveal an important mechanism by which
AERs could exert its glucose-lowering effects in patients with type 2
diabetes.
Methods
Animal studies. Animal studies were performed according to regulations issued by
the Swiss government and approved by the ethic veterinary committee of the canton
of Vaud - Switzerland (Permit ID 2250). Animals were housed and bred according to
standardized procedures50. Age-matched male mice were used for all experiments.
TGR5 genetically engineered mouse models were described earlier. Eight week-old
TGR51/1 and TGR52/2 mice were fed a HFD (60% cal/fat, D12492; Research Diets)
for 12 weeks or less as specified. Colestilan was admixed to the high fed diet at 2% (w/
w) and was given ad libitum to the mice during 2 weeks. Mice were sacrificed after
4 hours of fasting. For short-term Colestilan treatment, mice were initially fed a high
fat diet for 12 weeks, fasted for 4 hours from 3:00 pm to 7:00 pm and refed with high
fat diet pellets admixed with 2% (w/w) Colestilan during 3 hours prior to the GLP-1
secretion assay.
For the in vivo plasma GLP-1 measurements, mice were gavaged with the dipep-
tidyl-peptidase (DPP)-IV inhibitor sitagliptin (3 mg/kg) 60 min prior to the gavage
of Ensure Plus at a dose of 10 ml/kg (1.5 Cal/ml; Proteins: 15% of total Cal,
Carbohydrates: 57% of total Cal, Fat: 28% of total Cal; Abott). Blood was collected
(100 mL) from the tail vein at the indicated times, transferred to EDTA tubes con-
taining sitagliptin (Millipore), and kept on ice. Plasmawas collected by centrifugation
and transferred to ELISA plates to assess total GLP-1.
Ex vivo explant studies. For the intestinal explant study, diet induced obese mice
were fed a high fat diet containing 2% Colestilan for two weeks. Animals were
sacrificed and intestinal segments of 0.5 cm were dissected, cut into 5 smaller pieces,
washed in PBS and maintained in DMEM 10% FCS containing DPP-IV inhibitor.
After 4 hours, the tissues were exposed to either 30 mM INT-777 (6a-ethyl-23(S)-
methyl-cholic acid), or filtered colon content for 1 hour after which the supernatant
was frozen until total GLP-1 measurements were performed. Colon content was
obtained from 5 Colestilan-treated and 5 control-treated mice, which had been on a
high fat diet for 2 weeks. Colon content was pooled, resuspended in 3 ml of HBSS
medium (Sigma) and centrifuged at 4500 rpm for 15 min, after which the
supernatant was filtered through a 0.22 mm filter. The filtered solutions were diluted
1:10 and used in the TGR5 activation assay or used to treat colon explants as described
in the figure legends.
GLP-1 secretion. Total GLP-1 measurements were performed according to the
manufacturer’s instructions (Total GLP-1 (7–36) amide; K150JVC-1 Mesoscale
Discovery, Gaithersburg). For all GLP-1 assays, except for plasma measurements,
concentrations of GLP-1 were normalized against total protein amount.
Insulin and glucose measurements. Glucose was assessed with a glucometer
(Accucheck, Roche). Insulin wasmeasured by ELISA according to themanufacturer’s
instructions (Mercodia Uppsala, Sweden).
Transient Transfections and Reporter Assays. Cells were transiently transfected
with JetPei (Polyplus Transfection) according to the manufacturer’s protocol. CHO
cells were transiently transfected with TGR5 expression vector and a CRE-driven
luciferase reporter51. After 24 hours of incubation, medium was replaced by serum
free medium and cells were treated for 1 hour with the indicated compounds or with
the colon content from untreated or Colestilan-treated mice. Cells were then lysed in
Bright Glo reagent (Promega) and luciferase activity was determined as previously
described11. STC-1 and GLUTag enteroendocrine cells were transfected with a 2.3 kb
rat proglucagon luciferase reporter52 in the presence of either a shControl or shTGR5
vector as previously described14. After 24 hours of incubation, medium was replaced
by serum free medium and cells were treated for 4 hours with either vehicle or 30 mM
INT-777. Cells were then lysed in Bright Glo reagent (Promega) and luciferase
activity was determined as previously described11. Luciferase activity was normalized
against ß-galactosidase levels. Experiments were performed three times, and data
represent average values of quadruplicates of a representative experiment.
Quantitative RT-PCR. RNA was isolated from cells using TRIreagent (Ambion),
after which cDNA was synthesized (Qiagen). Quantitative RT-PCR was performed
using SYBR green (Roche) in the Lightcycler 480 II (Roche). All mRNA expression
levels were corrected for expression of the housekeeping gene 36B4 or b2-
microglobulin. Used primer sequences are available upon request.
Fecal lipid analysis. Fecal lipids were extracted essentially by using the method of
Folch53, andwere quantified using enzymatic assays. Briefly, feces were collected from
mice individually housed over a 24-h period. Aliquots of feces (100 mg) were dried
for 1 h at 70uC, incubatedwith 2 ml of chloroform-methanol (2:1) for 30 min at 60uC
with constant agitation, and then centrifuged. Water (1 ml) was added to the
supernatant, and following vortexing, phase separation was induced by low-speed
centrifugation (2,000 rpm for 10 min). The lower chloroform phase was then
removed and transferred to a new tube, and the sample was evaporated to dryness.
Samples were then resuspended in 500 ml chloroform-1% Triton X-100, evaporated
to dryness, and finally resuspended in 500 ml of water, so that the final solvent was 1%
Triton X-100 in water. The amount of total and free cholesterol (Wako, Neuss,
Germany), triglycerides (BioMerieux,Marcy l’Etoile, France), free fatty acids (Wako),
and phospholipids (Wako) in the fecal lipid extracts were then assayed using
enzymatic kits according to manufacturers’ protocols.
Fecal bile acids. Extraction and measurement of fecal bile acids were performed
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on a shaker table overnight. Two ml of KCl (3.7 g/L) were added and samples were
centrifuged for 10 min (1,500 g, 4uC). The supernatant was removed, evaporated to
dryness and dissolved in 1 ml of methanol-water (1:1, v/v). Bile acids were measured
at 340 nm by colorimetry.
Statistical analysis. Data represent the means 6 standard errors of the means.
Statistical analysis was performed using student’s t-test. In case ofmultiple testing, the
ANOVA test was used, followed by the student t test. A P,0.05 was considered
statistically significant.
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